Back

Linking intrinsic factor X activity, a biologically relevant pharmacodynamic marker, to edoxaban plasma concentration and clinical outcomes in the ENGAGE AF-TIMI 48 trial

27 August 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: New trends in antithrombotic therapy for atrial fibrillation Atrial fibrillation (AF) ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Ophelia Qiping Yin

Daiichi Sankyo Pharma Development, Edison, New Jersey (United States of America)

8 More presentations in this session

Presentation thumbnail
Real world persistence, adherence and switch-over across anticoagulants in atrial fibrillation-a national population-based study.
Doctor A. Banerjee (London, GB)
Abstract Slides Video
Presentation thumbnail
Patients with atrial fibrillation and history of falls are at high risk for bleeding but have less bleeding with apixaban than warfarin: results from the ARISTOTLE trial
Doctor M. Rao (Durham, US)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and active cancer: insights from the ARISTOTLE trial
Assistant Professor C. Melloni (Durham, US)
Abstract Slides Video
Presentation thumbnail
Direct oral anticoagulants in atrial fibrillation patients undergoing cardioversion. Nationwide multicentre study.
Miss S. Itainen-Stromberg (Helsinki, FI)
Abstract Slides Video
Presentation thumbnail
When should we start thromboprophylaxis? The stroke risk threshold discrepancy between European and U.S. guidelines for atrial fibrillation
Mr P. Nielsen (Aalborg, DK)
Abstract Slides Video

Access the full session

Session thumbnail
New trends in antithrombotic therapy for atrial fibrillation

The Event

Event poster

ESC Congress 2016

27 August - 31 August 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources